Latest News in the pharma Industry

Research & Development

Regulus expands clinical trial collaboration with GSK

Regulus expands clinical trial collaboration with GSK

1 Jun 2016

Phase II study evaluating the combination of RG-101 and GSK's long-acting parenteral formulation of GSK2878175 as a potential single-visit cure to begin Q4 2016

Read more 
ChemConnection and Cristal Therapeutics announce successful GMP production of CriPec Docetaxel for Phase I/IIa clinical trials

ChemConnection and Cristal Therapeutics announce successful GMP production of CriPec Docetaxel for Phase I/IIa clinical trials

1 Jun 2016

Read more 
Agile Sciences creates a powerful new weapon in the fight against antibiotic resistance

Agile Sciences creates a powerful new weapon in the fight against antibiotic resistance

1 Jun 2016

Their proprietary family of 2 Amino-Imadazole compounds renders bacteria incapable of mounting any kind of defense against antibiotics or other threats.

Read more 
Positive interim data from Phase II PoC study of evinacumab in patients with HoFH

Positive interim data from Phase II PoC study of evinacumab in patients with HoFH

31 May 2016

Interim data from the first four patients treated in this study showed that evinacumab added to current lipid-lowering therapy reduced low-density lipoprotein cholesterol levels by an additional 55% at week 4 compared to baseline.

Read more 
NIH funds biobank to support Precision Medicine Initiative Cohort Program

NIH funds biobank to support Precision Medicine Initiative Cohort Program

30 May 2016

$142 million will be awarded over 5 years to the Mayo Clinic to establish the world’s largest research-cohort biobank for the PMI Cohort Program, a longitudinal research study which aims to enroll 1 million or more US participants to advance precision ...

Read more 
Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes

Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes

30 May 2016

Results from the SUSTAIN 4 trial were presented at the American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress (AACE) in Orlando, US.

Read more 
New research from Accenture reveals gap in Pharma R&D’s journey to delivering better patient outcomes

New research from Accenture reveals gap in Pharma R&D’s journey to delivering better patient outcomes

26 May 2016

Adoption of digital transformation to drive patient outcomes may improve competitive position for pharma R&D organizations.

Read more 
Flex Pharma initiates human efficacy study with single molecule tablet in nocturnal leg cramps

Flex Pharma initiates human efficacy study with single molecule tablet in nocturnal leg cramps

26 May 2016

Single molecule TRP ion channel agonist in randomized, blinded, controlled, cross-over study.

Read more 
Macrolide Pharmaceuticals Scientific Founder publishes new findings on groundbreaking technology for novel macrolide antibiotics

Macrolide Pharmaceuticals Scientific Founder publishes new findings on groundbreaking technology for novel macrolide antibiotics

25 May 2016

The paper describes a innovative synthetic chemistry platform that enables access to novel macrolide antibiotics.

Read more 
Synergy Pharmaceuticals presents additional Phase III plecanatide data in CIC at DDW

Synergy Pharmaceuticals presents additional Phase III plecanatide data in CIC at DDW

22 May 2016

Both plecanatide 3 mg and 6 mg doses met the primary endpoint.

Read more 
Crown Bioscience launches HuScreen — a new high throughput service platform utilizing the largest available collection of PDX models

Crown Bioscience launches HuScreen — a new high throughput service platform utilizing the largest available collection of PDX models

19 May 2016

HuScreen will initially focus on popular indications such as colorectal, gastric, lung (small and non-small cell type), ovarian and breast cancer.

Read more 
FDA grants Genentech’s cancer immunotherapy Tecentriq Accelerated Approval for people with a specific type of advanced bladder cancer

FDA grants Genentech’s cancer immunotherapy Tecentriq Accelerated Approval for people with a specific type of advanced bladder cancer

18 May 2016

First and only anti-PDL1 cancer immunotherapy approved by the FDA.

Read more